Persistence with mirabegron therapy for overactive bladder: A real life experience
| Autor: | Nisha Pindoria, Arun Sahai, C. Kelleher, Claire Taylor, Sachin Malde, Jennifer Nowers |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class business.industry Urology 030232 urology & nephrology Retrospective cohort study medicine.disease Discontinuation 03 medical and health sciences 0302 clinical medicine Patient satisfaction Overactive bladder 030220 oncology & carcinogenesis Internal medicine medicine Anticholinergic Neurology (clinical) Young adult Mirabegron business Adverse effect medicine.drug |
| Zdroj: | Neurourology and Urodynamics. 36:404-408 |
| ISSN: | 0733-2467 |
| DOI: | 10.1002/nau.22943 |
| Popis: | Aims To evaluate persistence rates of patients receiving mirabegron therapy for overactive bladder (OAB) within our institution over a 6 month period, identify determinants of early discontinuation of therapy, and assess overall patient satisfaction with treatment. Methods Hospital prescription data were analyzed in order to identify all patients who had been prescribed mirabegron in our institution. Case notes were retrospectively reviewed to obtain demographic data, previous treatments for OAB, reasons for discontinuation of previous treatments, and duration of treatment with mirabegron. Overall satisfaction with treatment was assessed using the OAB Satisfaction with Treatment Questionnaire (OAB-SAT-q). Results One hundred and ninety-seven patients were prescribed mirabegron. Of these, 81% previously discontinued anticholinergic therapy, 14% had previously received intravesical botulinum toxin A therapy, and 19% were prescribed mirabegron first-line. At 3 months 69% persisted with treatment which fell to 48% by 6 months. The commonest reason for discontinuation was lack of efficacy, followed by adverse effects. Overall 32% of patients preferred mirabegron over previous treatments and only 39% were satisfied with mirabegron therapy. Conclusion Persistence rates with mirabegron in this group of patients for OAB are satisfactory. The commonest reasons for discontinuation are unmet treatment expectations and adverse effects. We had very few treatment-naive patients and so further studies are required to assess mirabegron persistence rates with longer-term follow up, as first-line treatment and in different groups of OAB severity. Neurourol. Urodynam. 9999:XX–XX, 2015. © 2015 Wiley Periodicals, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text